PARIS (Reuters) - Sanofi (SASY.PA) sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost ...

Bayer AG’s revenue will not plummet even though the company is facing patent expiries for some blockbuster drugs, according to its pharma head. “The patent cliff is more of a dent than a cliff,” ...

Sanofi has turned to one of its own to take the reins of its global diabetes and cardiovascular business. Stefan Oelrich, who’s been leading that operation in North America since July, is moving up to ...

Sanofi SA (SAN.FR) said Monday that it has appointed Stefan Oelrich to its executive committee as executive vice president, diabetes and cardiovascular. Since July, Mr. Oelrich has been acting head of ...

Sanofi has appointed Stefan Oelrich as executive vice president, diabetes and cardiovascular (DCV) and he will also join the executive committee. Oelrich has served as head of Sanofi’s global diabetes ...